the aid library

World Health Organization WHO (2021) C_WHO

10 May 2021 This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020. This update is focused on what is currently understood about SARS-CoV-2 ... more

Download

View PDF

Imunidade natural contra a COVID-19 Informe científico 10 de maio de 2021

Organização Mundial da Saúde (OMS) OPAS, OMS (2021) C_WHO

Natural immunity against COVID-19 Scientific report 10 May 2021

External Link

Comprehensive COVID-19 Slideset: Symptoms and Clinical Manifestations

Clinical Care Options (2021) CC

26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.

Download

View PDF

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt ... more

Download

View PDF

Bad Bug Book

Food and Drug Administration (FDA) (2013)

Handbook of Foodborne Pathogenic Microorganisms and Natural Toxins

Download

View PDF

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that polici ... more

Download

View PDF

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Chung, K. F.; Wenzel, S. E.; Brozek, J. L.; et al. (2022) CC2

The European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force on severe asthma includes an updated definition of severe asthma, a discussion of severe asthma phenotypes in relation to genetics, natural history, pathobiology and p ... more

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

Humanitarian Standards Pocket Guide

The Sphere Project; World Vision Singapore (2006)

Download

View PDF

Update 66 – COVID-19 vaccine booster doses

World Health Organization WHO (2021) CC

September 2021

Download

View PDF

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19 ... more

Download

View PDF

Democratic Republic of the Congo. Demographic and Health Survey 2013-14.Supplemental V accine -preventable Diseases Report

A. Rimoin; E. Okitolonda; R. Doshi; et al. USAID; WHO; PEPFAR; et al. (2015) C1

Download

View PDF

Diphtheria evidence to recommendations table

World Health Organization WHO (2017) C_WHO

Download

View PDF

Профилактика синдрома дефицита внимания с гиперактивностью у детей через скорочтение

Васильева Лидия Львовна Scientific Cooperation Center "Interactive plus" (2019) C2

Адаптивные технологии развития интеллектуальных способностей человека учитывают естественные интересы людей разных возрастных групп, позволяют оптимизировать ... more

Download

View PDF

Fourth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus

World Health Organization WHO (2016)

Download

View PDF

Vaccine misinformation management field guide

The Public Good Projects; UNICEF; First Draft, Yale Insitute for Global Health (2020) C_UNICEF

Guidance for addressing a global infodemic and fostering demand for immunization December 2020 Misinformation threatens the success of vaccination programs across the world. This guide aims to help organizations to address the global infodemic through the development of strategic and well-coordina ... more

Download

View PDF

Growing Stronger - 10 Key Steps for Growing Stronger with Resilience through the Corona Pandemic

Dr. Slama-Chaudhry, A. Ananke (2020) CC

We as a large world community are facing an extraordinary challenge: keeping healthy against the threat of rapidly spreading novel Covid-19 virus. Starting with flu-like symptoms, the virus attacks the airways leading to severe breathing difficulties in the m ost vulnerable, that is, those whose im ... more

Download

View PDF

Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended

Organización Mundial de la Salud OMS (2021) C_WHO

orientaciones provisionales, 14 de junio de 2021

Download

View PDF

Current recommendations for treatment of tetanus during humanitarian emergencies

World Health Organization (2010)

Download

View PDF

Technical considerations for implementing a risk-based approach to international travel in the context of COVID-19

World Health Organization WHO (2021) C_WHO

Interim guidanceAnnex to: Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19 recommended

Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended